| Comprehensive and integrative genomic characterization of hepatocellular carcinoma A Ally, M Balasundaram, R Carlsen, E Chuah, A Clarke, N Dhalla, RA Holt, ... Cell 169 (7), 1327-1341. e23, 2017 | 1837 | 2017 |
| Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan F Innocenti, SD Undevia, L Iyer, P Xian Chen, S Das, M Kocherginsky, ... Journal of Clinical Oncology 22 (8), 1382-1388, 2004 | 1160 | 2004 |
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ... Journal of Clinical Oncology 28 (22), 3617, 2010 | 985 | 2010 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 821 | 2017 |
| CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O'Neil, ... Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 2014 | 644 | 2014 |
| Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB … AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ... Journal of Clinical Oncology 34 (15_suppl), 3504-3504, 2016 | 485 | 2016 |
| Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer BM Wolpin, C Rizzato, P Kraft, C Kooperberg, GM Petersen, Z Wang, ... Nature genetics 46 (9), 994-1000, 2014 | 340 | 2014 |
| Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics F Innocenti, DL Kroetz, E Schuetz, ME Dolan, J Ramírez, M Relling, ... Journal of Clinical Oncology 27 (16), 2604, 2009 | 292 | 2009 |
| Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome F Innocenti, FS Ou, X Qu, TJ Zemla, D Niedzwiecki, R Tam, S Mahajan, ... Journal of Clinical Oncology 37 (14), 1217, 2019 | 275 | 2019 |
| Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue F Innocenti, GM Cooper, IB Stanaway, ER Gamazon, JD Smith, S Mirkov, ... PLoS genetics 7 (5), e1002078, 2011 | 269 | 2011 |
| ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ... Nature reviews Clinical oncology 17 (12), 757-770, 2020 | 264 | 2020 |
| Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated … E Cecchin, F Innocenti, M D'Andrea, G Corona, E De Mattia, P Biason, ... Journal of Clinical Oncology 27 (15), 2457-2465, 2009 | 253 | 2009 |
| Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance) HJ Lenz, FS Ou, AP Venook, HS Hochster, D Niedzwiecki, RM Goldberg, ... Journal of Clinical Oncology 37 (22), 1876, 2019 | 214 | 2019 |
| Ethnic differences and functional analysis of MET mutations in lung cancer S Krishnaswamy, R Kanteti, JS Duke-Cohan, S Loganathan, W Liu, ... Clinical Cancer Research 15 (18), 5714-5723, 2009 | 211 | 2009 |
| A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter W Liu, F Innocenti, MH Wu, AA Desai, ME Dolan, EH Cook Jr, MJ Ratain Cancer research 65 (1), 46-53, 2005 | 211 | 2005 |
| Effect of methylenetetrahydrofolate reductase 677C→ T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients G Toffoli, A Russo, F Innocenti, G Corona, S Tumolo, F Sartor, E Mini, ... International journal of cancer 103 (3), 294-299, 2003 | 209 | 2003 |
| A pharmacogenetic study of uridine diphosphate–glucuronosyltransferase 2B7 in patients receiving morphine MB Sawyer, F Innocenti, S Das, C Cheng, J Ramírez, FH Pantle‐Fisher, ... Clinical Pharmacology & Therapeutics 73 (6), 566-574, 2003 | 206 | 2003 |
| Clinical pharmacology and pharmacogenetics of gemcitabine A Wong, RA Soo, WP Yong, F Innocenti Drug metabolism reviews 41 (2), 77-88, 2009 | 202 | 2009 |
| Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups F Innocenti, C Grimsley, S Das, J Ramírez, C Cheng, H Kuttab-Boulos, ... Pharmacogenetics and Genomics 12 (9), 725-733, 2002 | 200 | 2002 |
| Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin K Zhou, SW Yee, EL Seiser, N Van Leeuwen, R Tavendale, AJ Bennett, ... Nature genetics 48 (9), 1055-1059, 2016 | 197 | 2016 |
